Ohbayashi Hiroyuki, Asano Takamitsu, Kudo Sahori, Ariga Mitsue
Department of Allergy and Respiratory Medicine, Tohno Chuo Clinic, Mizunami, Japan.
Pulm Ther. 2021 Jun;7(1):171-187. doi: 10.1007/s41030-021-00149-6. Epub 2021 Mar 2.
Inhalation therapy involves two types of adherence: adherence to the drug and adherence to the procedures for the inhalation device. User satisfaction and preference are key factors for maintaining good adherence of both types, and they should be evaluated based on three conditions being well maintained: asthma control level (ACL), adherence, and adequate device operability during usage duration. We compared user satisfaction and preference between a pressurized metered-dose inhaler (pMDI) and a dry powder inhaler (Ellipta), while maintaining the three conditions during usage in stable asthma patients.
In this open-label, randomized, two-way crossover study, patients with stable asthma [Asthma Control Questionnaire (ACQ) scores < 0.75] were classified into a 20-64-year age group (G1) and a ≥ 65-year age group (G2) and randomly assigned to either a formoterol/fluticasone combination (FFC) as the pMDI group or a vilanterol/fluticasone combination (VFC) as the Ellipta group. Satisfaction and preference levels were evaluated at week 4. ACL was measured using the ACQ and Japan Asthma Control Survey questionnaires at weeks 0 and 4. Device operability and respiratory resistance were also examined.
Forty-four patients (23 G1, age 45.8 ± 1.9 years; 21 G2, 74.1 ± 1.3 years) were enrolled and maintained good ACL during the study. Adherence to FFC pMDI and VFC Ellipta was > 97% in all groups. Device operability did not differ significantly between FFC pMDI and VFC Ellipta in the G1 (p = 0.189) or G2 (p = 0.506) group. Overall satisfaction was marginally higher with the FFC pMDI than with the VFC Ellipta in G2 (p = 0.012) but non-significantly different in G1 (p = 0.733). Factors affecting overall satisfaction in G2 were difference of inhalation device and body mass index. Respiratory resistance did not change significantly over the study in G2.
Based on maintaining good ACL, adherence, and device operability, FFC pMDI showed significantly higher satisfaction and preference levels than VFC Ellipta in elderly persons.
Japan Registry of Clinical Trials identifier, jRCTs041180001 (registered 21 August 2018).
吸入疗法涉及两种依从性:对药物的依从性和对吸入装置使用程序的依从性。用户满意度和偏好是维持这两种良好依从性的关键因素,应基于哮喘控制水平(ACL)、依从性以及使用期间装置的充分可操作性这三个条件得到良好维持来进行评估。我们在稳定期哮喘患者使用过程中维持这三个条件的同时,比较了压力定量吸入器(pMDI)和干粉吸入器(Ellipta)之间的用户满意度和偏好。
在这项开放标签、随机、双向交叉研究中,稳定期哮喘患者[哮喘控制问卷(ACQ)评分<0.75]被分为20 - 64岁年龄组(G1)和≥65岁年龄组(G2),并随机分配到作为pMDI组的福莫特罗/氟替卡松联合制剂(FFC)或作为Ellipta组的维兰特罗/氟替卡松联合制剂(VFC)。在第4周评估满意度和偏好水平。在第0周和第4周使用ACQ和日本哮喘控制调查问卷测量ACL。还检查了装置的可操作性和呼吸阻力。
44例患者(G1组23例,年龄45.8±1.9岁;G2组21例,74.1±1.3岁)入组并在研究期间维持良好的ACL。所有组中对FFC pMDI和VFC Ellipta的依从性均>97%。G1组(p = 0.189)或G2组(p = 0.506)中,FFC pMDI和VFC Ellipta之间的装置可操作性无显著差异。G2组中,FFC pMDI的总体满意度略高于VFC Ellipta(p = 0.012),但G1组无显著差异(p = 0.733)。影响G2组总体满意度的因素是吸入装置和体重指数的差异。G2组在研究期间呼吸阻力无显著变化。
基于维持良好的ACL、依从性和装置可操作性,FFC pMDI在老年人中显示出比VFC Ellipta显著更高的满意度和偏好水平。
日本临床试验注册中心标识符,jRCTs041180001(2018年8月21日注册)。